Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹14,552 Cr
Revenue (TTM)
₹5,092 Cr
Net Profit (TTM)
₹545 Cr
ROE
14.5 %
ROCE
16.2 %
P/E Ratio
26.7
P/B Ratio
3.5
Industry P/E
48.01
EV/EBITDA
14.2
Div. Yield
0.3 %
Debt to Equity
0.3
Book Value
₹166.8
EPS
₹22.3
Face value
1
Shares outstanding
247,796,921
CFO
₹3,886.71 Cr
EBITDA
₹6,053.88 Cr
Net Profit
₹3,379.45 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Granules India
| -1.9 | 3.2 | 1.3 | 20.2 | 27.1 | 12.8 | 17.4 |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Granules India
| 0.2 | 43.8 | 27.2 | -5.2 | -6.4 | 188.9 | 35.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Granules India
|
587.2 | 14,551.9 | 5,092.5 | 545.5 | 15.9 | 14.1 | 26.7 | 3.5 |
| 2,257.8 | 18,500.8 | 1,215.1 | 284.8 | 28.7 | 21.1 | 64.5 | 12.2 | |
| 676.3 | 13,282.8 | 7,266.8 | 627.5 | 11.9 | 12.6 | 21.1 | 2.4 | |
| 306.3 | 11,719.9 | 2,051.5 | 180.5 | 11.6 | 7.7 | 58.1 | 3.1 | |
| 856.6 | 13,645.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 31.5 | 2.1 | |
| 957.9 | 17,149.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11 | 2.0 | |
| 1,471.6 | 16,867.1 | 1,419.3 | 20.1 | 8.4 | 0.5 | 839.1 | 2.9 | |
| 143.1 | 19,028.2 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 419.9 | 16,903.3 | 3,720.2 | 352.1 | 13.7 | 8.2 | 48 | 3.6 | |
| 1,215.6 | 19,800.5 | 3,151.0 | -10.0 | 8.4 | 2.5 | 900 | 4.3 |
Stock Rating update, March 15, 2024
2 min read•By Value Research
Why is this paracetamol maker bleeding?
4 min read•By Hemkesh Khattar
Companies falling short of cash
2 min read•By Rajan Gulati
1 min read•By Research Desk
1 min read•By Research Desk
6 min read•By Value Research
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, Africa, the Middle East, and internationally.... The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers various FDs, such as tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; and other products for oncology. The Company also exports its products. Granules India Limited was founded in 1984 and is based in Hyderabad, India. Read more
Incorporated
1991
Chairman
Krishna Prasad Chigurupati
Managing Director
Krishna Prasad Chigurupati
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Granules India Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Granules India Ltd is ₹587.15 (NSE) and ₹587.25 (BSE) as of 18-Mar-2026 IST. Granules India Ltd has given a return of 27.09% in the last 3 years.
The P/E ratio of Granules India Ltd is 26.68 times as on 18-Mar-2026, a 44 discount to its peers’ median range of 48.01 times.
The P/B ratio of Granules India Ltd is 3.52 times as on 18-Mar-2026, a 15 premium to its peers’ median range of 3.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
23.56
|
3.19
|
|
2024
|
25.71
|
3.25
|
|
2023
|
13.62
|
2.50
|
|
2022
|
18.40
|
2.96
|
|
2021
|
13.67
|
3.49
|
The 52-week high and low of Granules India Ltd are Rs 627.00 and Rs 422.00 as of 19-Mar-2026.
Granules India Ltd has a market capitalisation of ₹ 14,552 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Granules India Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹15.15
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.